Apellis Pharmaceuticals
Global biopharma company leveraging courageous science, creativity, and compassion to deliver life-changing therapies.
Waltham, United States
769 employees
Post-IPO Debt
Total: $643.53M
Biotechnology, Health Care +2
General Information
Waltham, United States
BounceWatch is an independent company data service, not affiliated with Apellis Pharmaceuticals. To contact Apellis Pharmaceuticals, visit apellis.com.
Is this your company?
Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.
Get Verified
How does Apellis Pharmaceuticals compare?
A PDF of Apellis Pharmaceuticals and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.
This takes a few seconds: we look beyond our own index too.
Meeting Apellis Pharmaceuticals soon?
A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample
From the desk
Is Apellis Pharmaceuticals on your competitive set?
Our desk can watch it and brief you on every move: hiring, funding, leadership, product and pricing.
Book a 7-day ReadoutDiscover More
United States Market
Biotechnology
About Apellis Pharmaceuticals
Business keywords: Biopharma, Therapeutics, Drug Delivery, Chronic Inflammatory Diseases, Asthma, Chronic Obstructive Pulmonary Disease, Complement Cascade, Ophthalmology, Nephrology, Hematology, Neurology, Paroxysmal Nocturnal Hemoglobinuria, Gene Therapy, Amyotrophic Lateral Sclerosis
Funding Rounds & Investors (11)
View All| Funding Stage | Amount | Investors | Lead Investors | Date |
|---|---|---|---|---|
| Post IPO Debt | $475.00M | 1 |
|
14 May 2024 |
| Post IPO Equity | Undisclosed | 1 |
|
01 Jan 2020 |
| Series E | $60.00M | 9 |
|
10 Aug 2017 |
| Series D | $47.00M | 6 |
|
12 Feb 2016 |
| Series C | $33.00M | 3 |
|
02 Dec 2014 |
| Venture Round | $6.00M | 1 |
|
02 Aug 2013 |
| Venture Round | $17.84M | - |
|
30 Jul 2013 |
| Non Equity Assistance | $20.00K | 1 |
|
05 Apr 2013 |
| Series B | Undisclosed | 1 |
|
18 Jul 2012 |
| Series A | $2.97M | 4 |
|
20 Jun 2011 |
Apellis Pharmaceuticals Alternatives & Competitors
View All Alternatives
Amira Pharmaceuticals is a small molecule pharmaceutical company focused on the discovery and early...
Pioneering therapies to combat neurodegenerative diseases with innovative protein disaggregation tec...
FAQ About Apellis Pharmaceuticals
Source: BounceWatch company record for Apellis Pharmaceuticals, https://bouncewatch.com/company/apellis-pharmaceuticals, updated 20 July 2026. When citing, please name BounceWatch and link this page.
